Aims: Anti-vascular endothelial growth factor agents effectively treat age-related macular degeneration and myopic choroidal neovascularization (CNV). Tissue plasminogen activator (tPA), a fibrinolytic compound, is used as an adjuvant to displace submacular hemorrhage and to treat type 2 CNV. The purpose of this study was to investigate in in vitro and in vivo experiments the antiangiogenic impact of tPA itself. Methods: The impact of tPA on the proliferation of human umbilical vein endothelial cells (HUVECs) was assessed by an XTT assay [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide]. A basic fibroblast growth factor-impregnated gelatin hydrogel sheet was implanted into the rabbit cornea to induce corneal neovascularization. Immediately postoperatively, tPA or buffered saline solution (control) was injected intravitreally. Results: The growth and viability of the HUVECs were unaffected by tPA at clinical concentrations. In the control group, the mean lengths of the new vessels were 1.0 ± 0.41, 1.6 ± 0.75, and 3.6 ± 2.1 mm at weeks 1, 2, and 4, respectively. In contrast, tPA significantly (p < 0.01) reduced the corneal neovascularization. Conclusion: Although tPA has no direct impact on the vascular endothelial cells in vitro, the fibrinolytic effects of tPA might markedly suppress neovascularization in vivo.

Keywords:
Angiogenesis, Corneal neovascularization, Human umbilical vein endothelial cells, Rabbit, Tissue plasminogen activator
1.
Bressler NM: Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291: 1900–1901.
2.
Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, Iida M, Ishibashi T: Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population: the Hisayama study. Ophthalmology 2009; 116: 2135–2140.
3.
Kawasaki R, Wang JJ, Ji GJ, Taylor B, Oizumi T, Daimon M, Kato T, Kawata S, Kayama T, Tano Y, Mitchell P, Yamachita H, Wong TY: Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 2008; 115: 1376–1381, e1–e2.
4.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Chung CY, Kim RY; MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
5.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
6.
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537–2548.
7.
CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
8.
Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, Blodi BA, Elner SG: Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999; 106: 1900–1906; discussion 1906–1907.
9.
Kadonosono K, Arakawa A, Yamane S, Inoue M, Yamakawa T, Uchio E, Yanagi Y: Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air. Ophthalmology 2015; 122: 123–128.
10.
Meyer CH, Scholl HP, Eter N, Helb HM, Holz FG: Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 2008; 86: 490–494.
11.
Mizutani T, Yasukawa T, Ito Y, Takase A, Hirano Y, Yoshida M, Ogura Y: Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 2011; 249: 1153–1157.
12.
Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y: Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998; 116: 1326–1332.
13.
Kachi I, Yasukawa T, Kato A, Takase N, Morita H, Kubota A, Hirano Y, Uemura A, Ogura Y: Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization. Jpn J Ophthalmol 2016; 60: 179–186.
14.
Ozone D, Mizutani T, Nozaki M, Ohbayashi M, Hasegawa N, Kato A, Yasukawa T, Ogura Y: Tissue plasminogen activator as an antiangiogenic agent in experimental laser-induced choridal neovascularization in mice. Invest Ophthalmol Vis Sci 2016; 57: 5348–5354.
15.
Yang CF, Yasukawa T, Kimura H, Miyamoto H, Honda Y, Tabata Y, Ikada Y, Ogura Y: Experimental corneal neovascularization by basic fibroblast growth factor incorporated into gelatin hydrogel. Ophthalmic Res 2000; 32: 19–24.
16.
Gimbrone MA Jr, Cotran RS, Leapman SB, Folkman J: Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974; 52: 413–427.
17.
Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG: Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol 2014; 158: 128–135, e10.
18.
Ying GS, Kim BJ, Maguire MG, Huang J, Daniel E, Jaffe GJ, Grunwald JE, Blinder KJ, Flaxel CJ, Rahhal F, Regillo C, Martin DF; CATT Research Group: Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 2014; 132: 915–921.
19.
Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161–195.
20.
Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ: The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992; 667: 1–12.
21.
Rakic JM, Lambert V, Devy L, Luttun A, Cameliet P, Claes C, Nguyen L, Foidart JM, Noël A, Munaut C: Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3186–3193.
22.
Rakic JM, Lambert V, Munaut C, Bajou K, Peyrollier K, Alvarez-Gonzalez ML, Cameliet P, Foidart KM, Noël A: Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 1732–1739.
23.
Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ: Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839–5847.
24.
Lambert V, Munaut C, Carmeliet P, Gerard RD, Declerck PJ, Gils A, Claes C, Foidart JM, Noël A, Rakic JM: Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophthalmol Vis Sci 2003; 44: 2791–2797.
25.
Diebold I, Kraicun D, Bonello S, Gorlach A: The “PAI-1 paradox” in vascular remodeling. Thromb Haemost 2008; 100: 984–991.
26.
Irvine WD, Johnson MW, Hernandez E, Olsen KR: Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol 1991; 109: 718–722.
27.
Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN: Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990; 108: 259–263.
28.
Hrach CJ, Johnson MW, Hassan AS, Lei B, Sieving PA, Elner VM: Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol 2000; 118: 659–663.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.